The findings indicated that the use of sorafenib as a maintenance treatment decreases the likelihood of relapse and mortality following HCT for FLT3 ITD-positive AML, with a 24-month RFS rate of 85%, compared to 53.3% in the placebo group [42]. This evidence concerns the gene FLT3 and acute myeloid leukemia.